Multiple Sclerosis Center

Clinical Research & Clinical Trials

Title

Protocol

Sponsor

Study Status

Clinical Research Coordinator

A Randomized, Double-Blind, Double Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sclerosis

WA21092/3

Genentech-Hoffman-LaRoche

New Study, Enrollment Period TBA

Angela Campbell
Phone: 650-721-6188
Email » [ajcampbell]

JC Virus Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Natalizumab: The STRATIFY-2 Study

101JC402

Biogen-Idec

Study Active, Enrollment Ongoing

Daniel Lebus
Phone: 650-723-3657
Email » [dklebus]

Multicenter, randomized, double blind parallel group extension to study AC-058B202 to investigate the long term safety, tolerability, and efficacy of 10, 20 and 40 mg/day ACT-128800 (Ponesimod), an oral S1P1 receptor agonist, in patients with relapsing remitting Multiple Sclerosis

 

Actelion

Study Active, Enrollment Closed

Angela Campbell
Phone: 650-721-6188
Email » [ajcampbell]

A Phase III Randomized, Rater and Dose Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three Times weekly Subcutaneous Interferon Beta-1a in Patients with Relapsing Remitting Multiple Sclerosis who have Relapsed on Therapy

CAMMS32400597
Stanford Protocol #16988

Genzyme Corporation; Cambridge, MA

Study Active, Enrollment Closed

Angela Campbell
Phone: 650-721-6188
Email » [ajcampbell]

A Longitudinal, Case-Control Study to Collect Medical and Epidemiological Data and Blood Samples for Research Into the Causes of Multiple Sclerosis and Selected Demyelinating Diseases

Stanford Protocol 17667

Accelerated Cure Project

Study Active, Enrollment Ongoing

Daniel Lebus
Phone: 650-723-3657
Email » [dklebus]

Blood and CSF Repository to Identify Biomarkers in Multiple Sclerosis (in collaboration with May Han, MD; Stanford University; Stanford, CA)

Stanford Protocol # 16691

unrestricted MS translational research training grant

Study Active, Enrollment Ongoing

Daniel Lebus
Phone: 650-723-3657
Email » [dklebus]

Immune Modulation by Alemtuzumab in Multiple Sclerosis (in collaboration with Wendy Gilmore, PhD; USC; Los Angeles, CA):

Stanford Protocol # 16988

 

Study Active, Enrollment Closed

Angela Campbell
Phone: 650-721-6188
Email » [ajcampbell]

An Extension Protocol For Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab

CAMMS03409

Genzyme Corporation; Cambridge, MA

New Study, Enrollment Closed

Angela Campbell
Phone: 650-721-6188
Email » [ajcampbell]

 

Stanford Medicine Resources:

Footer Links: